<DOC>
	<DOCNO>NCT00583102</DOCNO>
	<brief_summary>The purpose study test safety effectiveness combine drug know Lovastatin chemotherapy drug cytarabine . Lovastatin currently use low blood cholesterol level lab data suggests increase anti-leukemia activity cytarabine . This research do high dos cytarabine induce remission 25 % patient acute myeloid leukemia .</brief_summary>
	<brief_title>Dose Escalation Phase I/II Study Lovastatin With High-Dose Cytarabine Refractory Relapsed AML</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Lovastatin</mesh_term>
	<mesh_term>L 647318</mesh_term>
	<mesh_term>Dihydromevinolin</mesh_term>
	<criteria>Patients primary refractory AML ( prior remission ) . Patients great 10 % AML blast bone marrow blood upon recovery two cycle standard cytarabine anthracyclinebased induction chemotherapy eligible . Patients receive etoposide and/or 6thioguanine remission induction eligible . Patients relapse AML . Patients must document remission last &gt; 30 day point prior therapy . Their current relapse must untreated . Relapse define presence great 10 % AML blast bone marrow blood document remission . Patients receive highdose cytarabine contain regimen ( &gt; 2 g/m2/dose ) within 3 month prior registration protocol eligible . No active CNS involvement . A lumbar puncture prior treatment require perform absence significant CNS symptom sign . Nonpregnant nonnursing . Treatment protocol would expose unborn child significant risk . Women men reproductive potential agree use effective mean birth control . Although NOT consider formal Exclusion Criteria , study physician strongly encourage part decisionmaking process recognize follow may increase risk subject enter protocol : Other serious illness would limit survival &lt; 2 year , psychiatric condition would prevent compliance treatment informed consent . Performance Status &gt; 2 . Uncontrolled severe cardiovascular disease , diabetes , pulmonary disease , infection , opinion treat physician , would make protocol treatment unreasonably hazardous patient . Patients `` currently active '' second malignancy nonmelanoma skin cancer . Patients consider `` currently active '' malignancy complete therapy consider physician less 30 % risk relapse within one year . Patients receive investigational agent within prior 4 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Lovastatin</keyword>
	<keyword>Cytarabine</keyword>
</DOC>